Using SELDI-ToF MS technology, a set of potential serum biomarkers for glioblastoma diagnostic was assessed, finding three proteins, chemokine CXCL4, as well as S100A8 and S100A9 proteins as putative GBM biomarkers, whose serum levels in glioblastoma were increased in comparison with controls [359]. Here, S100A9 is linked to glioblastoma.